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ABSTRACT: About 70 to 75% of patients with nonseminomatous te ticular germ cell tumors (NSs) 
present with metastases. When these metastases are treated with chemotherapy, often residual mature 
teratoma (RMT) is left. RMT is composed of fully differentiated somatic tissue. Untreated metastases of
NSs rarely consist exclusively of mature somatic tissue. Apparently, after chemotherapy treatment there 
is a shift towards higher degrees of differentiation. Investigating tumor progression and the mecha- 
nism(s) involved in therapy-related differentiation, we compared the cytogenetically abnormal karyo- 
types of a series of 70 NSs with those of 3I RMTs. In NSs and RMTs, the modal total chromosome 
number does not differ and is in the triploid range. Both the frequency and the average copy number of 
i(12p) are the same, and the pattern of chromosomal over- and underrepresentation and distribution of 
breakpoints do not differ significantly in these series. So, we found the chromosomal pattern of RMTs as 
abnormal as those of primary NSs. Based on cytogenetics, we found no indication that specific chromo- 
somal alterations parallel metastasis and therapy-related differentiation of the metastases. The cytogenetic 
data suggest that both induction of differentiation of(selected) cells or selection of cells with capacity to dif- 
ferentiate are possible mechanisms for the therapy-related differentiation of RMTs, © Elsevier Science 
Inc., 1997 
INTRODUCTION 
Primary nonsenl inomatous testicular germ cell tumors 
(NSs) of adults are, in general, tumors with mixed histol- 
ogy. They can be composed of embryonal carcinoma (EC), 
yolk sac tumor (YS), choriocarcinoma (CH), immature ter- 
atoma (IT), and mature teratoma (MT) [1, 2]. A seminoma 
(SE) component may be present. Pure NSs, with one histo- 
logical component,  are rare [3]. At presentation, about 70 
to 75% of patients with NSs have lymphatic and/or 
hematogenous metastases. However, NSs are highly cur- 
able solid tumors. The patients are treated by orchidec- 
tomy, in case of metastatic disease, fol lowed by cisplatin- 
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containing chemotherapy and addit ional surgical resection 
of residual mass [4]. 
From metastases of primary NSs treated with chemo- 
therapy, often residual mature teratoma (RMT) is left. RMT 
is composed of fully differentiated, mature somatic tissue. 
As is the case in primary tumors, untreated metastases of 
pr imary NSs rarely consist exclusively of mature somatic 
tissue; they usual ly retain the histology of the primary 
tumor [5]. Apparently,  after chemotherapy there is a shift 
towards higher degrees of differentiation. This effect of 
chemotherapy might be due to the induction of differenti- 
ation of malignant cells to more differentiated cells, to se- 
lective destruction of cells other than MT cells, or to 
selection of cells with an inherent capacity of (therapy- 
related) differentiation. The mechanisms are not mutual ly 
exclusive [6]. 
Cytogenetic omparison of pr imary tumors and me- 
tastases may indicate chromosomal changes playing a role 
in tumor progression. Tumor progression is the result of 
clonal evolution of a tumor cell population, paral leled by 
karyotype volution [7]. 
We compared the cytogenetical ly abnormal karyotypes 
of a series of 70 NSs with those of 31 RMTs, in order to 
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Tab le  I 
Case a 
1 
2 
3 
4 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Description of the modal  composite karyotype and the modal  chromosome number of 31 RMTs 
Description of modal composite karyotype 
61-79,XX,-Y,+ 1,+6,+8,+9,+ 10,+i(12)(p10),+ 13,+ 17,- 18,+ 21,+mar[cp7] 
42-60,XXY,-1, -2, -3, -4, -5, -9,  10,+i(12)(p10)×2,-13,-14,-15, 8,-19,-20,+mar[cp18] 
62-63,XXY,-8,i(12)(p10),+i(12)(p10) x 2,-  13,- 14, 18,-20,del(22)(q12)[cp2] 
56-59,XX,-Y,add(1)(p36),der(2)t(2;8)(q32;q23),- 3 , -4 , -  5, 9,-10,-11,+i(12)(p10)x2,-13, 
dic(13;17)(p11;q22),-14,-15,-16,-17, 18,-19, 20,add(22)(q11),+2mar[cp13] 
59-62,XXY,der(1)t(1;3)(p32;p21),-2, 4,-5,der(7)t(5;7)(q13;q22),-10, 11,+i(12)(p10)x3, 
13,- 14,- 15,add(17)(q25),- 18,- 19,+21,- 22[cp31 
63-65,XXY,+del(1)(q41),-4,-5,+ 7,+ 8,add(9)(p13),- 10, 10,- 11,+i(12)(p10),- 13,- 14,- 15, 
del(16)(p13),- 18,- 19,+mar[cp4] 
49-54,XX,-Y,del(1)(p34), 2, -3, -4,  5,der(5)t(3;5)(q21;p15),-6,+add(7)(q22),-9, 10,add(10) 
(q26), 11,-13,-14,-15,-16,del(17)(p11), 18,-18, 19,-20,-21, 22,+der(?)t(?;18)(?;q11), 
+mar[cp14] 
54-58,XXY,-2,-3,-4,-9,-9,-10,-10,-11,+i(12)(p10)x2, 13,-14, 15,-16,-18,del(18)(p11), 
-19, 21,-22,+der(?)t(?;9)(?;q11),+ 2mar[cp6] 
52-56,XXY,del(1)(p375), 2, -3, -4,  5,+6,-9, 10,-11,+add(12)(p13),+i(12)(p10)x2,-13,-14, 
-15, -16, -18,  19,-20,-21,-22[cp9] 
56-58,XXY,add(1)(p11),add(1)(p34),-2,-3, 4 5 -8,del(8)(p22), 9,-10,-11,+i(12)(p10)x2, 
-13,-14,  14,-15,-16,-18,-19, 20,+21,-22,+2mar[cp9] 
78-88,XXY,+ 1,+2,+3,+ 3,+add(5)(q31), 6,add(7)(p11),der(7)t(7;7)(p22;q11),+inv(7)(p15p22), 
+8,+9,+del(lO)(p13),add(11)(q25),+ 1 ,+ del(12)(q21q24),+i(12)(p10) x 3,+13,+ 14,+ 17,+20, 
+21, 22,- 22,i(22)(q10),+der(?)t(?;7)(?;p10),+mar[cp18] 
57-66,XXY,+Y, 1, -4, -5,  6,+7,+7,+del(7)(q31),-8,-10, 11,+i(12)(p10),-13, 14,-17,-18, 
- 19,+ 21,-22,+ der(?)t(?;5)(?;q13),+mar[cp9] 
55-57,XY,-X,add(1)(p36), 4 , -6, -9,  10,-11,+i(12)(p10)x2,-13,-14,-15,-18, 19,-20, 
-21,-22[cp9] 
62-66,XY,+Y,del(X)(p21)+add(1)(p36),der(2)t(1;2)(q21;q37), 4,+7,-9, 10,-11,+i(12)(plO)X2, 
add(13)(p11),-14, 18,-19, 20,-22[cp9] 
56-59,XXY,+ X,dic(1;20)del(1)(20qter-~20p13::lq44-~lq12::1q21-~1p34), 2,-3,-4,del(4)(p15), 
-5,add(7)(q11),-9, 10,-11,add(11)(q23),add(12)(q24),+i(12)(p10)x2,-13, 14,- 5,-16, 18, 
- 19,-20,-  21,der(22)t(7;22)(q11;q13)[cp7] 
57-62,XXY,+y,+der(1)t(1;6)(p34;p21),-2,-4,-9,- 10  11,+i(12)(p10),- 13,- 14,- 15, 18,-19, 
add(20)(p13),+add(20)(p13),- 22[cp9] 
47-53,XX,-Y,del(1)(p21),del(1)(p35),-2, 4, -5, -6,  9,-10, 11,add(11)(q23),del(12)(q13), 
+dic(12;15)(p13;p13),+i(12)(p10),-13, 14,-15,-15,dic(15;20)(q26;p13), 6,-18, 19, 
add(19)(q13), 20,- 20,- 21,add(21)(q22),der(21)t(1;21)(p31;p13),- 22,add(22)(p13), 
+ der(?)t(?;5)(?;q13)[cp11] 
54-63,XX,-Y,add(1)(p32),+add(1)(q21),+ del(1)(p22),del(2)(q33),dic(2;?6)(p25;q21),-4, 
+del(8)(p12),+der(8)t(1;8)(p22;p11),-9, 10 +i(12)(p10)x2, 13,-15, 16,-18,-18, 
i(18)(q10),- 19,-21,-  22,+ 2mar[cpl0] 
61-66,XXY,add(1)(p36) x2,+del(1)(q11),+del(2)(p24),-4,- 5,+add(6)(p22),+8,-9,- 10, 
+i(12)(p10)x2,-13,dic(13;13)(p12;p12), 14,-15,add(15)(p12),-16, 18,-19,de1(20) 
(p12),-22,+mar[cp101 
60-65,XXY,+Y,del(1)(p34),der(1)t(1;5)(q23;q13),-4,- 5,+der(6)t(6;7)(q11;p11),+ der(8)t(8;9) 
(p21;q11),-9, 10,-11,+i(12)(p10)x2,-13, 14,-15, 16,-18, 19,+20,+21,-22,+mar[cp11] 
Modal 
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study chromosomal changes playing a role in tumor pro- 
gression (e.g., metastasis) and/or the mechanism(s) in- 
volved in therapy-related differentiation. A distinction 
between both events cannot be made because, due to the 
appl icat ion of standardized cl inical protocols, we are not 
able to investigate the chromosomal pattern of untreated 
metastases of NSs. 
MATERIALS AND METHODS 
A cytogenetic omparison of 70 NSs with 31 RMTs was 
carried out. Culturing and harvesting of the tumors was 
performed using standard cytogenetic techniques [8, 9]. 
For each tumor, a modal composite karyotype description 
was made according to the ISCN 1995 [10]. However, all 
karyotype descriptions are based on the tr iploid level, 
since this makes over- and underrepresentation of specific 
chromosomes- -an important feature of testicular germ cell 
tumors [9, 11]--better visible and comparable. Only NSs 
and RMTs with an abnormal karyotype are included in 
this study, because NSs and RMTs show a consistently 
high DNA index (DI) [12-16]. 
For each tumor and chromosome, the average number 
of short and long arms was determined. Parts of chromo- 
somal arms involved in structural abnormalit ies were reg- 
Chromosomal  Pat tern  Compar i son  after Chemotherapy  
Tab le  I Cont inued 
61 
Modal 
Case Description of modal composite karyotype number 
21 56-60,XXY,der(1)t(1;4)(p11;q11),- 2,add(2)(p25),-4,-  5 , -6 , -  6,dup(7)(q11.2q21),+8,- 9 , -  10, 59 
- 11,add(11)(q24),- 13,-  16,-  17,-  18,+mar[cp6] 
22 57-59,XY,-X,add(1)(p36),- 2 del(3)(p21),-4,- 7,+i(8)(q10),- 9 , -  10, -  11,+i{12)(p10),- 13,-  13, 58 
- 14,-  15,del(16)(p13),der(16)t(?;16)(q11;q24),- 18,-  19,-  20,+der(?)t(?;13)(?;q12)[cp7] 
23 54-64,XXY,del(1)(p11),-4,- 5 dic(5;5)(p15.3;p15.3),+ der(7)t(7;7)(q31;p11.2),- 11 +i(12) 61 
(pl0) x 2 , -  14,add(14)(p 13),- 15, -  16,-  18,-  19,add(20)(p12), + 21,-  22 [cpl0] 
24 47-59,XXY,+Y,add[1)(p36),der(2)t(2;9)(p23;q11),-4,- 5 , -  8 , -  9 , -  9 , -  10,-  11,-  13,add(14)(p13), 58 
- 15,add(16)(q22),- 18,-  19, -  20,+mar[cpl0] 
25 57-64,XXY,+X,add(1)(p36),- 2 , 4 , -  5,+add(7)(q21),der(8)t(8;21)(p11;q21),-9,- 10  11, 60 
+i(12)(p10)x2, -13, -  14,-  15,-  16,-  18, 19,+ 21, -  22,+ 2mar[cpl0] 
26 47-58,XXY,add(1)(p36),-2,del(3)(p23),-4, 5,-6,+add(7)(q22),add(8)(p23),- 9 , -  10,add(10) 56 
(q26),- 11,+add(12)(p13) x2 , -  13,-  14,-  15,-  16,del(17)(p11),- 18,-  20,der(20)t(6;20) 
(p11;p13),-22[cp4] 
27 57-62,XXY,add(1)(p13),add(2)(q11),- 3,add(3)(q26),- 4,add(5)(q35),add(7)(p22),der(7) 58 
t(7;7;18)(Tqter-~7p22::7qll--Wq34::18q11-~18qter),+add(8)(p23),-9,- 10,-  1 ,add(14) 
(q32),- 15,-  18,-  18,der(18)t(2;18)(q14;p11),add(19)(ql 2), -  20, -22,+ 3mar[cpl0] 
28 50-61,XXY,add(1)(q32),add(1)(p36),- 2 , -4 , -  5 , -  6 ,+8, -9 , -  10,-  11,+i(12)(p10),- 13, -  15, 58 
-16,i(17)(q10),-18,-19,-19,add(19)(q13), 20,+ der(?)t(?;12)(?;p11),+mar[cp10] 
29 56-62,XXY,+Y,add(1)(pl l) ,add(2)(q13),-3,-4,-5,-6,add(6)(q16),+add(7)(q32),-  9,der(9) 60 
t(6;9)(q11;q21),der(10)t(9;10)(q21;q21)- 11,+i(12)(p10)x 2 , -  13,-  15,-  17,-  18, -  19,add(19) 
(p13),- 22,+ 2mar[cpl0] 
30 56-82,XXY,add(1)(p34),add(2)(p13), 4, -5,  9 , -10 , -11 ,+ i (12) (p10)x2 , -13 , -14 , -15 , -18 ,  59 
-19 , -20 ,  22,+2mar[10] 
31 59-62,XXY,del(1)(p35),- 2,add(3)(p12),-4,-  5,+del(8)(p11),- 9 , -  10,add(10)(q22),- 11, -  13, 61 
14,-15,-18,-19,der(20)t(12;20)(p11;p11),+ 2 , 22,+2mar[cp10] 
aCases I to 13 have been described previously (Castedo et el. [17]) 
i s tered as who le  arms if they  represented  50% or more  of 
the  total  a rm length.  The moda l  number  of shor t  and  long 
arms d iv ided  by two revea led  the average moda l  number  
of chromosomes .  The  average number  of sex chromosomes  
for each tumor  was mul t ip l ied  by two to a l low compar i son  
w i th  the autosomes  [9, 11]. 
Stat ist ical  ana lys is  and  compar i son  of the cytogenet ic  
data of the  NSs and  RMTs was per fo rmed us ing  the Mann-  
Tab le  2 Histo logica l  components  of 70 NSs 
Case Histology Case Histology Case Histology Case Histology 
1 YS;CH;EC;MT 21 EC;MT 41 YS;CH;EC;IT;MT 
2 EC;IT;MT 22 YS;EC;IT;MT;SE 42 EC;MT 
3 YS;EC 23 YS;CH;EC;MT 43 YS;EC;MT 
4 MT 24 YS;EC;IT;MT;SE 44 YS;EC;IT;MT 
5 YS;EC;IT;MT;SE 25 EC;IT;MT 45 IT;MT 
6 YS;EC;MT 26 EC;IT;MT 46 YS;EC 
7 YS;EC;IT;MT 27 YS;EC;IT;MT 47 MT 
8 MT 28 YS;IT;MT;SE 48 YS;EC 
9 EC 29 YS;CH;EC;IT;MT 49 YS;CH;EC;IT;MT;SE 
10 EC;MT 30 YS;CH;EC;IT;MT 50 EC 
11 EC;MT;SE 31 YS;EC;MT;SE 51 EC;IT;MT 
12 EC;SE 32 YS;EC;IT;MT 52 CH;EC;MT 
13 YS;EC;IT;MT 33 YS;EC 53 EC;IT;MT 
14 YS;EC;IT;MT 34 YS;EC;IT;MT;SE 54 YS;EC;IT;MT 
15 YS;CH;EC;IT;MT 35 EC;IT;MT;SE 55 EC 
16 MT;SE 36 EC;IT;MT 56 YS;SE 
17 EC;IT;MT 37 YS;EC;MT 57 CH;EC;MT;SE 
18 YS;EC;IT;MT 38 YS;IT 58 MT;SE 
19 YS;EC 39 YS;EC;IT;MT;SE 59 EC;MT 
20 YS 40 YS;EC;IT;MT 60 EC;SE 
61 YS;IT;MT 
62 YS;MT 
63 YS;EC;IT;MT 
64 MT 
65 YS;MT 
66 YS;IT;MT 
67 EC;IT 
68 YS;EC;IT;MT 
69 EC;MT 
70 YS;EC;IT;MT 
Abbreviations: YS, yolk sac tumor; CH, choriocarcinoma; EC, embryonal carcinoma; MT, mature teratoma; IT, immature teratoma; 
SE, seminoma. 
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Whitney U or chi-square test with Bonferroni's correction 
for mult iple testing, when necessary. 
RESULTS 
Karyotypes 
The modal  composite karyotypes and the modal chromo- 
some numbers for the 31 chromosomally abnormal cases 
of RMTs are given in Table 1. Cases 1 to 13 have been pub- 
l ished [17], as well  as the 70 chromosomally abnormal 
NSs [9]. Table 2 shows the histological components of the 
70 NSs. From 10 patients, both the primary NS and the 
RMT were analyzed (cases of NS and RMT respectively: 7 
and 11, 13 and 14, 14 and 15, 16 and 16, 17 and 17, 24 and 
20, 32 and 26, 45 and 27, 46 and 30, 49 and 29). 
Statistical Analysis and Comparison of NSs and RMTs 
The Mann-Whitney U test showed no significant differ- 
ence between the modal total chromosome number in NSs 
(average, 65.0; standard deviation [SD], 13.5; n = 70) and 
RMTs (average, 60.5; SD, 6.5; n = 31) (p > 0.053). Figure 1 
clearly shows that the average number of copies of the dif- 
ferent chromosomes i highly similar in the series of NSs 
and RMTs (Spearman rank correlation: 0.918, p < 0.001). 
In RMTs and NSs, a similar pattern of overrepresentation 
(e.g., chromosomes 7, 8, 12, 21, and X) and underrepresen- 
tation (e.g., 11, 13, 18, and Y) is present. Addit ional ly,  
Figure 2 shows this similar pattern of over- and underrep- 
resentation of (parts of) chromosomes (Fig. 2A has been 
publ ished before [9]). Chromosome arm 12p was clearly 
overrepresented, mainly due to i(12p), in NSs and RMTs. 
No significant difference in number of copies of the differ- 
ent chromosomes was observed when groups of NSs with- 
out a teratoma component (n = 12), NSs with a teratoma 
component (n = 58), and RMTs (n = 31) were compared 
(p > 0.05). 
Both the frequency of i(12p) (83% in NSs and 81% in 
the RMTs) as well  as the average copy number of i(12p) 
(1.7; SD, 1.0 in the NSs and 1.5; SD, 0.9 in the RMTs) did 
not differ significantly between NSs and RMTs (p > 0.05). 
Figure 3 shows the number and location of breakpoints 
in each chromosome in the 70 NSs and 31 RMTs. The dis- 
tr ibution of breakpoints in both groups does not differ 
significantly (p > 0.001). In both the NSs and RMTs, a 
Figure 1 Average modal number per chromosome in a group of 70 NSs (dark line} and 31 RMTs (thin line) (see 
Materials and Methods for the calculation of modal numbers). The average number of the sex chromosomes for 
each case was multiplied by two to allow comparison with the autosomes. In addition, the average number of 
short and long arms of chromosome 12 is indicated separately (circles = 12p and 12q NS; rectangles = 12p and 
12q RMT). 
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clustering of breakpoints was found in chromosome 1 and 
12 (p ~ 0.001); for chromosome 12, mainly due to i(12p). 
DISCUSSION 
Cytogenetic comparison of primary tumors and metastases 
may indicate chromosomal changes playing a role in 
tumor progression. Tumor progression is the result of 
clonal evolution of a tumor cell population and is paral- 
leled by karyotype volution [7]. Due to clonal evolution 
and selection, malignant tumors are genetically heteroge- 
neous and contain multiple subpopulations of cancer 
cells. Only certain subpopulations of tumor cells have the 
capacity to form metastatic lesions [18]. Due to the appli- 
cation of standardized clinical protocols, we are not able 
to investigate the chromosomal pattern of untreated 
metastases of NSs. It is only possible to study residual 
lesions following chemotherapy--often r sidual mature 
teratoma (RMT). These RMT lesions are composed of fully 
differentiated tissue [6]. This higher degree of differentia- 
tion after chemotherapy treatment might be due to direct 
induction of differentiation of malignant cells to fully dif- 
ferentiated cells, to selective destruction of cells other 
than MT cells, or to selection of cells with an inherent 
capacity of spontaneous differentiation orcapacity of ther- 
apy-related differentiation [6, 17, 19-21]. 
A cytogenetic comparison between NSs and RMTs may 
shed light on the chromosomal changes playing a role in 
tumor progression and on the mechanism(s) of therapy- 
related ifferentiation, although adistinction between these 
events cannot be made. 
The present study, a cytogenetic comparison of a series 
of 70 NSs and 31 RMTs, revealed no significant chromo- 
somal differences between the two groups. This may be 
explained in different ways. 
First, by clonal dominance. This means that during 
progression a primary tumor gradually becomes over- 
grown by the progeny of a metastatic clone. This primary 
tumor consists almost exclusively of cells of this dominant 
metastatic clone and is biologically equivalent to the me- 
tastasis [22]. The cells of the primary tumor and the 
metastasis will show identical or very similar karyotypes. 
Under the influence of therapy, the metastatic cells differ- 
entiate irrespective of their highly abnormal karyotype. 
Second, the observed chromosomal similarities be- 
tween NSs and RMTs might be due to in vitro selection 
during culture. The histology of primary NSs in general is 
heterogeneous. RMT is most often found when the pri- 
mary tumor contains MT [6]. It might be that this MT com- 
ponent populates the RMT and is selected in the culture of 
the primary NS. 
Third, one would not expect o find chromosomal dif- 
ferences between primary NSs and RMTs, when metasta- 
sis is not caused or accompanied by visible chromosomal 
alterations and when RMTs are the result of therapy- 
related induction of differentiation ofcells, irrespective of 
their chromosomal pattern [17]. If RMTs are the result of 
selection or of differentiation of selected cells with an 
abnormal chromosomal pattern, but with a proper bal- 
anced chromosomal constitution allowing differentiation, 
one might only expect specific chromosomal differences 
between the primary NSs and RMTs [17] when different 
directions or degrees of differentiation are brought about 
by differences in chromosomal pattern. However, in an NS 
and a metastatic NS, respectively, we observed comparable 
karyotypes in the different pure histological components, 
which were karyotyped separately [23, 24]. Furthermore, 
in our series of NSs with pure histology [9], although 
small, we have no indications that the different histologi- 
cal components have different specific chromosomal con- 
stitutions. These data suggest that, in NSs, differences in 
direction of differentiation are not accompanied by gross 
chromosomal changes. Therefore, when RMTs are the re- 
sult of differentiation of selected cells, and when metasta- 
sizing and differentiation are not paralled by visible 
chromosomal terations, one also may observe common 
karyotypes between the primary NSs and RMTs. 
So, based on cytogenetics, both induction of differenti- 
ation or selection of cells with capacity to differentiate are 
possible mechanisms for the therapy-related differentia- 
tion of RMTs. In two different studies, Oosterhuis et al. [6, 
12, 25] found their results being compatible with selection 
as the mechanism of therapy-related differentiation. 
In a previous cytogenetic comparison of a series of 14 
NSs and 13 RMTs, we observed some differences between 
NSs and RMTs (e.g., smaller over- and underrepresenta- 
tion of specific chromosomes and less i(12p)-copies and 
breakpoints in RMTs than in NSs). These findings lead us 
to conclude that RMTs are the result of selection of clones 
with a less abnormal karyotype and possibly the right bal- 
ance of genes allowing differentiation [17]. In our present, 
much larger series of NSs and RMTs, we found no evi- 
dence for the selection of clones with a less abnormal 
karyotype. However, selection of cells is still a possible 
mechanism. 
Murty et al. [26] found that well-differentiated terato- 
mas exhibited a significantly higher level of allelic loss 
compared to the less differentiated embryonal carcinomas. 
Their results led them to suggest that nonrandom loss or 
inactivation of certain genes may be associated with tumor 
development and that loss or inactivation of other genes 
may be associated with somatic differentiation. Cytogenet- 
ically, we did not find a significant difference in loss of 
specific chromosomal parts in RMTs compared to primary 
NSs with different histologies. 
In conclusion, the two groups of primary NSs and 
RMTs showed comparable chromosomal patterns. We 
found no cytogenetic evidence for specific chromosomal 
alterations to be related to the progression of primary NSs 
to metastasis and/or therapy-related differentiation. Both 
induction of differentiation of (selected) cells or selection 
of cells with capacity to differentiate are possible mecha- 
nisms for the therapy-related differentiation of RMTs. 
Genetic changes not detectable at the chromosomal level 
or epigenetic factors may play a role in the tumor progres- 
sion and/or in the therapy-related differentiation of these 
tumors. It might be that most chromosomal changes re- 
lated with tumor progression i  NSs take place very early 
during tumor development, probably when the non-inva- 
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